Sermorelin

Sermorelin is a laboratory-made copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends down to the pituitary gland to tell it to let go of a pulse of growth hormone. Natural GHRH is 44 amino acids long; the first 29 carry essentially all of the activity, which is why the shortened version works. That makes sermorelin unusual among the peptides sold online: it is not an experimental compound but a former prescription medicine. The US Food and Drug Administration approved it as Geref in December 1990 as a single-injection test of whether a person's pituitary can still make growth hormone, and again in September 1997 at higher doses as a daily treatment for children with idiopathic growth hormone deficiency. EMD Serono asked to discontinue both products in 2008, approval was withdrawn in June 2009, and in 2013 the FDA formally determined that the withdrawal was not for reasons of safety or effectiveness. Everything sold as sermorelin today is compounded or research-grade material, not the approved product.

• Diagnosing growth hormone deficiency: a single intravenous dose, then blood draws to see whether the pituitary responds. This is the use the approved drug was best characterised for
• Treating idiopathic growth hormone deficiency in prepubertal children, which is what the 1997 approval covered
• Raising your own nightly growth hormone output rather than injecting growth hormone itself, which is the reason clinics and online sellers offer it to adults
• Body composition goals: less fat, more lean mass. The two small trials in older adults that looked at this found changes only in men, and only with a modified version of the peptide
• Sleep, on the reasoning that the largest natural growth hormone pulse happens during early deep sleep. In the one trial that asked, sleep quality did not change

Think of your pituitary as a tap that opens a few times a day and lets out a measured amount of growth hormone. GHRH is the hand that turns the tap; sermorelin is a copy of the fingers that actually grip it. Because it works through the tap rather than pouring hormone in from outside, the plumbing still sets the limit: the pituitary decides how much comes out, and the body's own brake hormone, somatostatin, can still shut the flow off. The grip also lets go quickly, since the peptide is cleared from the blood in roughly ten to twenty minutes.

1. First doseGrowth hormone rises within minutes. In 30 healthy men given GHRH(1-29) intravenously, as little as 0.25 micrograms per kilogram produced a measurable release, the peak response came at 1 to 2 micrograms per kilogram, and growth hormone stayed elevated for about three hours even though the peptide itself was cleared fast (Wilton et al., 1993).
2. Week 2-4This is when blood markers move, if they move at all. In older adults on a nightly modified version of the peptide, insulin-like growth factor 1 (IGF-1) and its binding protein IGFBP-3 rose within two weeks and immune cell markers shifted within four (Khorram et al., 1997). In healthy elderly men on sermorelin itself, nocturnal growth hormone rose but IGF-1 never did (Vittone et al., 1997).
3. Week 6Six weeks of nightly 2 mg sermorelin in eleven elderly men changed no measure of body weight, body mass index, waist-to-hip ratio or DEXA-measured muscle and fat. Two of six strength tests improved. That is the whole published adult body-composition record at this time point (Vittone et al., 1997).
4. Month 4In children given 30 micrograms per kilogram nightly, height velocity went from 4.1 cm a year at baseline to 8.0 cm a year by six months (Thorner et al., 1996). In age-advanced adults on the modified analog for 16 weeks, lean body mass and insulin sensitivity rose in men but not women, and the IGF-1 rise had already started falling back toward baseline by week 16 (Khorram et al., 1997).
5. Post-cycleNo published study has followed adults after stopping. In the pediatric program the growth benefit depended on continued treatment, and the effect of long-term daily sermorelin on final adult height was never established before the drug was withdrawn (Prakash and Goa, 1999).

• Pain, swelling or redness at the injection site. This was among the two most commonly reported adverse events in the review of the approved product's clinical data (Prakash and Goa, 1999).
• Transient facial flushing, the other most common reported event, which follows the injection and settles.
• Transient hyperlipidemia (raised blood fats) was the only adverse effect recorded in the 5-month trial of the modified analog in older men and women, and it had resolved by the end of the study (Khorram et al., 1997).
• Injection-site reactions, fluid retention, joint and muscle aching, and disturbances of blood sugar are the adverse-effect categories a 2026 review of GH-axis peptides lists for this class as a whole, including GHRH analogues (Dominikowski et al., 2026).
• In the 110-child treatment study no adverse changes in biochemistry or hormone panels were seen, fasting glucose did not change, and IGF-1 was not driven to excessive levels over 12 months (Thorner et al., 1996). That is a real finding, at a dose several times larger than the cheatsheet figure, in children rather than adults.

• You are pregnant, trying to conceive, or breastfeeding. There is no human pregnancy data for sermorelin.
• You have an active cancer or a history of one. Growth hormone and IGF-1 are growth signals, and a 2026 review of this peptide class describes the mitogenic concern as biologically plausible but unproven; approved growth hormone products carry a neoplasm warning.
• You have a pituitary tumour, a history of pituitary surgery or radiation, or growth hormone deficiency caused by damage to the pituitary itself. Sermorelin asks the pituitary to release hormone it may not be able to make.
• You have diabetes, prediabetes or poor glucose control, and you are not monitoring it. Dysglycaemia is a reported concern for the class.
• You have an untreated thyroid problem, since low thyroid hormone blunts the growth hormone response to GHRH.
• You are an athlete subject to drug testing. Sermorelin is named on the World Anti-Doping Agency Prohibited List and validated mass-spectrometry methods for detecting it and its metabolites in urine have been published.
• You are a child or adolescent, unless a paediatric endocrinologist is directing treatment. This was a prescription drug for exactly that group, prescribed and monitored by specialists.
• You are not under a physician who can measure IGF-1, fasting glucose and HbA1c before and during use.

• Assuming the cheatsheet dose matches the studied dose. The trials used 30 micrograms per kilogram nightly in children, about 2,100 micrograms for a 70 kg person, and 2,000 micrograms nightly in elderly men. The 300 micrograms on the cheatsheet is a fraction of that, and no study has tested it.
• Eating shortly before the injection. Carbohydrate and a rise in free fatty acids both blunt the growth hormone response to GHRH, which is why the timing on the cheatsheet is before sleep on an empty stomach.
• Reconstituting roughly: use bacteriostatic water, run it down the inside of the glass rather than straight onto the powder, and swirl instead of shaking. Sermorelin is a short peptide that degrades at its own N-terminus, and rough handling does not help.
• Storing the mixed vial badly. Keep it cold and dark on a shelf rather than in the fridge door, where the temperature cycles every time it opens, and do not leave it out at room temperature for days.
• Expecting it to do what injected growth hormone does. In the one trial that compared them head to head in children, height standard deviation score for bone age improved only in the growth hormone group, not in either sermorelin group (Neyzi et al., 1993).